Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Ibio Inc. maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area with 2 pending office actions. Both of these 2 actions are being handled by 1 distinct examiner. This concentration suggests that the company's current pending applications are closely related or falling under the same specific technical jurisdiction.
The 1 distinct examiner involved is GREEN, MALIA NICOLE, who is also the busiest examiner with 2 busiest examiner pending office actions. This means GREEN, MALIA NICOLE is responsible for the entirety of the company's current pending workload. Furthermore, all activity is located within 1 distinct art unit, reinforcing the specialized nature of the Biotechnology & Pharmaceuticals filings.
From a prosecution standpoint, having 2 pending office actions with 1 distinct examiner in 1 distinct art unit allows for a consistent strategy. The practitioner only needs to address the specific perspectives of GREEN, MALIA NICOLE. The 2 busiest examiner pending office actions represent the total current administrative challenge for Ibio Inc. in this technology area.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GREEN, MALIA NICOLE | 2 | — | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18484635 | EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III ANTIBODIES | GREEN, MALIA NICOLE | — |
| Art Unit | Apps |
|---|---|
| 1643 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18489983 | CHEMOKINE RECEPTOR 8 (CCR8) ANTIBODIES | GREEN, MALIA NICOLE | 1643 | §112 | Non-Final OA | — | Pending | Oct 19, 2023 |
| 18484635 | EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III ANTIBODIES | GREEN, MALIA NICOLE | 1643 | §103§112 | Non-Final OA | — | Pending | Oct 11, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial